[A Case of Renal Cell Carcinoma with High Everolimus Blood Concentrations and Hyperglycemia Due to Everolimus-Induced Hepatic Dysfunction].
We report the case of a patient who had renal cell carcinoma with high everolimus blood concentrations and hyperglycemia due to everolimus-induced hepatic dysfunction. A 74-year-old man who underwent right nephrectomy for renal cell carcinoma was administered everolimus for multiple lung metastases. Everolimus caused grade 3 hepatic dysfunction and hyperglycemia; hence, high blood levels of everolimus were observed. Although the patient was re-administrated everolimus after recovering from hepatic dysfunction, hepatic function test values worsened again. Everolimus was discontinued before its blood concentration increased, and the patient was switched to axitinib treatment. Therefore, the measurement of everolimus blood level is considered useful for the management of adverse events in renal cell carcinoma.
Dept. of Pharmaceutical Sciences, Tohoku University Hospital.
Shinya
S
Takasaki
Masafumi
M
Kikuchi
Yoshihide
Y
Kawasaki
Akihiro
A
Ito
Yoichi
Y
Arai
Hiroaki
H
Yamaguchi
Nariyasu
N
Mano
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D056486:Chemical and Drug Induced Liver Injury; D017024:Chemotherapy, Adjuvant; D000068338:Everolimus / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced*; D007680:Kidney Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008107:Liver Diseases; D008111:Liver Function Tests; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male
D000970:Antineoplastic Agents; D000068338:Everolimus